Insulet/$PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Ticker
$PODD
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,900
ISIN
US45784P1012
Website
Insulet Metrics
BasicAdvanced
$21B
54.36
$5.55
1.27
-
Price and volume
Market cap
$21B
Beta
1.27
52-week high
$329.33
52-week low
$173.00
Average daily volume
851K
Financial strength
Current ratio
4.474
Quick ratio
3.239
Long term debt to equity
125.212
Total debt to equity
131.405
Interest coverage (TTM)
8.27%
Profitability
EBITDA (TTM)
423
Gross margin (TTM)
70.39%
Net profit margin (TTM)
18.29%
Operating margin (TTM)
15.50%
Effective tax rate (TTM)
-37.08%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
6.94%
Return on equity (TTM)
37.92%
Valuation
Price to earnings (TTM)
54.36
Price to revenue (TTM)
9.623
Price to book
15.95
Price to tangible book (TTM)
17.99
Price to free cash flow (TTM)
75.356
Free cash flow yield (TTM)
1.33%
Free cash flow per share (TTM)
400.26%
Growth
Revenue change (TTM)
23.49%
Earnings per share change (TTM)
67.51%
3-year revenue growth (CAGR)
24.41%
10-year revenue growth (CAGR)
23.44%
3-year earnings per share growth (CAGR)
105.57%
10-year earnings per share growth (CAGR)
18.44%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Bulls say / Bears say
Insulet Corporation reported a 29% year-over-year revenue increase in Q1 2025, indicating strong demand for its Omnipod products. (Insulet Corporation)
The company achieved a gross margin of 72.1% in Q4 2024, reflecting improved operational efficiency and profitability. (BioSpace)
Insulet expanded its international presence by launching Omnipod 5 integrated with Abbott’s FreeStyle Libre 2 Plus CGM sensor in multiple European countries, potentially increasing its market share. (TradingView News)
In Q2 2024, Insulet recorded a $13.5 million charge for unutilized inventory, negatively impacting gross margin by approximately 280 basis points. (Reuters)
The company's adjusted profit per share in Q2 2024 was $0.55, slightly below analysts' expectations of $0.56, indicating potential challenges in meeting market forecasts. (Reuters)
Insulet's larger competitor, Dexcom, reduced its annual forecast in July 2024, raising concerns about changing trends in the diabetes market that could affect Insulet's growth. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Insulet News
AllArticlesVideos
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Investors Business Daily·2 days ago
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Business Wire·2 weeks ago
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $21B as of July 03, 2025.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 54.36 as of July 03, 2025.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.